Aera Therapeutics’ Post

Exciting News: GenEmbryomics gears up for a major milestone in our journey towards global expansion. We're thrilled to announce the appointment of Saadia Basharat, a distinguished industry expert based in San Diego, to our Board of Directors! Saadia's wealth of experience in healthcare, biotechnology, and strategic business development will be invaluable as we prepare for listing on a major US national exchange. "Saadia’s deep understanding of the pharmaceutical and biotech industries, combined with her expertise in program strategy and business development, will undoubtedly enhance our capabilities in navigating the complex landscape of medical genetics," says Nick Murphy, PhD, GenEmbryomics' Founder and CEO. Join us in welcoming Saadia aboard as we chart our course toward continued growth and innovation! Learn more about GenEmbryomics and our GenomeScreen testing at genembryomics.com. #GenEmbryomics #MedicalGenetics #CorporateGovernance #USListing #Innovation #Biotechnology #genomics #genetics #reproductivegenetics #genetichealth #BioTechAdvances #genomicresearch #genomicinnovation #DNASequencing #Bioinformatics #GenomicRevolution #biotech #innovationingenomics #GenomicBreakthrough #GenomeMapping #PGTWGS

📖 SATURDAY HEADLINES: Beckman Coulter Life Sciences Accelerates Drug Discovery with Launch of Cydem VT Automated Clone Screening System “Through providing early answers and better cultivation conditions, we are able to ensure greater accuracy with fewer steps to reduce the risk of bad clones to help laboratories discover their next big breakthrough even faster and positively impact human health," said Product Manager Dr. Sebastian Hofzumahaus. Full story in The Scientist: https://lnkd.in/eD6PUu2q #DanaherNews #CloneScreening #mAbs

Is your current #AAV process holding you back? Join Fletcher Malcom at Bio-Expo Live 2024 (hosted by Bioprocess Online) for a presentation exploring the short and long-term impacts of process optimization on your gene therapy pipeline. Topics to be covered: ✅ A proprietary economic model which quantitates the impact of #upstream process optimization with varying #transfection technologies using real world case studies. ✅ Fold improvements in AAV titer and percent full capsids as a result of different transfection technologies with batch cost and cost-per dose comparisons. #upstreampd #bioprocess #bioprocessing #genetherapy #celltherapy #processdevelopment #manufacturing #scaling #gmp

27.11.2024 | Today our Scientific Director Csaba Boglári, Ph.D. will give a talk at the Genotoxicity Session of the OpenTox Virtual Conference 2024: https://lnkd.in/dME8VH7s The presentation will include the latest testing results from our study conducted on Nitrosamines using miniaturized Ames assays. 📅 Register for the event here: https://lnkd.in/dbEXTpJb 🌐 For more information, materials and resources, please visit our website: https://www.xenometrix.ch/ 📧 Further inquiries can be sent to cbo@xenometrix.ch #Nitrosamines #GenotoxicImpurities #VirtualConference #OpenTox #Talk #Presentation #Discussion #ScienitficExchange #AmesMPF #MicroAmes6 #AmesTest #MiniaturizedAmesTest #Mutagenicity #BacterialReverseMutation #MetabolicActivation #EnhancedAmesTest #HamsterS9 #AcceptableIntake #EMA #FDA #Volatile #NonVolatile #Cytotoxicity #AdjustedProtocols #ResourceEfficientTesting #NAMs #LowestEffectiveConcentration #Sensitivity #Specificity

UGenome Value #3. Trust Trust for us means being honest and transparent with what we believe our capacities are, then delivering on the goals for the project for the clients to give people better healthcare options. We believe in constructive candor. We value open and honest communication, embracing diverse opinions and constructive feedback to drive problem-solving and growth. #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics, #science, #dna, #research, #genomics, #medicine, #immunology, #drugdiscovery, #datascience, #lifesciences, #biostatistics, #health, #pharma, #genomeannotation, #pharmacogenomics, #pharmacogenetics, #genomicmedicine, #sequencing, #dataanalysis, #machinelearning, #precisionmedicine, #metagenomics,

Working with single-cell data? Join BenevolentAI and Rancho Biosciences for an informative discussion of how single-cell transcriptomics data at scale is helping to revolutionize drug discovery by providing deeper insights into cellular mechanisms. https://lnkd.in/gYweQWK9 In these presentations we will discuss: - The importance of high-quality data to produce meaningful insights and the robust workflows created to deliver analysis-ready single-cell transcriptomics datasets at scale - Introduction to BenevolentAI’s target discovery platform as illustrated by several cases studies that demonstrate its utility for mechanistic drug discovery. - How to prepare volumes of high-quality data for meaningful insights Learn how these innovative, AI-driven, disease agnostic approaches can transform your research, and lead to more effective, novel drug discovery outcomes more rapidly. #DrugDiscovery #SingleCellTranscriptomics #AIinHealthcare #Biotechnology #DataScience #PrecisionMedicine #ResearchInnovation #CellularMechanisms #BenevolentAI #RanchoBiosciences #HighQualityData #MechanisticInsights #PharmaceuticalResearch #HealthcareInnovation

📍Team 𝐀𝐫𝐲𝐚𝐬𝐭𝐡𝐚 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 is live at the 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 in San Diego! 📍 Our scientific experts –𝐑𝐚𝐠𝐡𝐚𝐯 𝐑𝐞𝐝𝐝𝐲 and 𝐏𝐫𝐚𝐝𝐢𝐩 𝐌𝐚𝐣𝐮𝐦𝐝𝐞𝐫 are meeting and exploring delegates to discuss their drug discovery and development journey. One of the interesting meet was with Switzerland based company 𝐅𝐥𝐮𝐨𝐒𝐩𝐡𝐞𝐫𝐚 who have developed a tissue multiplexing technology that predict drug safety and efficacy in systemic conditions to de-risk the discovery of small molecules and biologics much better and to discover the most promising molecules for patients. During the discussion with 𝐂𝐥𝐞𝐥𝐢𝐚 𝐁𝐨𝐮𝐫𝐠𝐨𝐢𝐧𝐭 and 𝐆𝐫𝐞𝐠𝐨𝐫𝐲 𝐒𝐞𝐠𝐚𝐥𝐚, we learnt that the solutions developed by FluoSphera uniquely combine high-throughput screening (HTS) with color-coded tissue multiplexing coupled to omics analysis to screen drugs under systemic conditions. We are so excited to meet & greet people from all around the bio pharma world and gain insights about upcoming new technologies and advances. Aryastha is also excited taking lead to talk about the TOX study in animal models. If you think this is something that interests you, meet us at Bio🤝 Discover more https://aryastha.com/ #BIOInternational #BIO2024 #SanDiego #LifeSciences #DrugDiscovery #DrugDevelopment #Innovation #AryasthaLifeSciences #FluoSphera #PharmaTech #TOXStudy #MeetTheExperts #BiotechConference #PharmaceuticalResearch #HealthcareInnovation #ScientificAdvancements Raghava Reddy Kethiri Gregory Segala Clélia Bourgoint BIO International Convention FluoSphera

UGenome Value #3. Trust Trust for us means being honest and transparent with what we believe our capacities are, then delivering on the goals for the project for the clients to give people better healthcare options. We believe in constructive candor. We value open and honest communication, embracing diverse opinions and constructive feedback to drive problem-solving and growth. #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics, #science, #dna, #research, #genomics, #medicine, #immunology, #drugdiscovery, #datascience, #lifesciences, #biostatistics, #health, #pharma, #genomeannotation, #pharmacogenomics, #pharmacogenetics, #genomicmedicine, #sequencing, #dataanalysis, #machinelearning, #precisionmedicine, #metagenomics,

Veronica Venafra now at #BITS2024. This presentation will explore how SignalingProfiler integrates multi-omics data to identify phenotypic hallmarks, facilitating new approaches in drug repurposing. #Bioinformatics #MultiOmics #DrugRepurposing 

#TrendingTuesday Exciting News in Genomics! 🚀 The global market for single nucleotide polymorphism (#SNP) is set to skyrocket from $32.0 billion in 2024 to an impressive $85.5 billion by 2029! 🚀📈 With a #CAGR of 21.7% during this period, the future of #genomic research and #personalizedmedicine looks incredibly promising! 💡🧬 Increasing applications of SNPs in many areas is driving the market. The global market for SNP genotyping applications is primarily driven by the #pharmaceuticals and #pharmacogenomics segment, which accounts for a projected share of 36.8% in 2024. Explore our detailed #report to learn more: https://bit.ly/3zT9Xdj #Biotech #MarketGrowth #Innovation #Healthcare #FutureOfMedicine #MarketTrends #Biotechnology #GeneticResearch #BCCResearch #SNPMarket #InvestmentOpportunity #Genotyping #Bioinformatics #MarketResearch #NextGenSequencing #ClinicalResearch #ResearchAndDevelopment